Clinical Trial Update: Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial exploring Envafolimab and Lenvatinib combined with VP-16 for platinum-resistant recurrent epithelial ovarian cancer is underway; current status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Envafolimab (envafolimab)
• Lenvatinib (lenvatinib)
• VP-16 (etoposide)

Snippet

Sponsor: Zhongda Hospital | Conditions: Ovarian Cancer, Epithelial | Phase 2 | Status: UNKNOWN